Researchers at the University of California, Davis have developed a gene therapy that selectively targets KSHV-infected tumors through virus-specific sequences and suicide genes to induce tumor cell death.

Researchers at the University of California, Davis have discovered FOXO inhibition using compounds such as AS1842856 dramatically enhances alpha-defensin expression in human intestinal organoids, restoring antimicrobial peptide levels comparable to native tissue.

Researchers at the University of California, Davis have developed a technology for the treatment of neuropsychiatric and neurological diseases with compounds that enhance neural plasticity without the hallucinogenic effects.

Researchers at the University of California, Davis have developed an algorithm that uses data from group testing to rapidly provide lifestyle optimizations that improve the health of patients.

Researchers at the University of California, Davis have developed a technology that provides a method for treating traumatic brain injury (TBI) using a therapeutically effective dose of a selective cyclin-dependent kinase 4 (CDK4)/cyclin-dependent kinase 6 (CDK6) inhibitor.

Researchers at the University of California, Davis have developed a novel approach to treating traumatic brain injury (TBI) and other acute neurological disorders using the FDA-approved cancer drug, dasatinib.

Researchers at the University of California, Davis have developed a combinatorial cancer treatment that enhances IL-15 mediated immune activation while inhibiting STAT3 to suppress myeloid-derived immune suppression in bone and soft tissue sarcomas.

Researchers at the University of California, Davis have developed polypeptide compositions of the peripheral nervous system tau isoform ("big tau") that appear to selectively enhance kinesin-3 motor activity and bias intracellular transport toward anterograde direction to treat diseases linked to impaired axonal transport.

Researchers at the University of California, Davis have developed a rheologically stabilized composition that enables improved viability and function of therapeutic cells delivered endoscopically for intestinal luminal diseases.

A novel chemically inducible platform that directs arginine methylation to target proteins, enabling their selective lysosomal degradation.

Researchers at the University of California, Davis have developed methods to treat medulloblastoma by restoring calcium signaling that promotes neuronal differentiation and inhibits tumor growth.

Researchers at the University of California, Davis have developed AAV-mediated gene therapy that delivers the choline acetyltransferase (ChAT) gene to treat presynaptic congenital myasthenic syndromes and related neuromuscular disorders.

Researchers at the University of California, Davis in collaboration with Iff Technologies have developed a hybrid quantum-classical computational workflow that enhances protein-protein binding site identification by quantum-assisted pruning of molecular structures prior to classical docking.

Researchers at Louisiana State University, New Orleans and the University of California, Davis have developed neuroprotective compounds that inhibit glutamine transport to reduce excitotoxic glutamate release, offering treatment for neurodegenerative diseases.

A mechanistic discovery linking amyloid beta (Aβ)-associated neurodegeneration with chronic pain after peripheral nerve injury, revealing Aβ as a novel therapeutic target.

Brief description not available

Brief description not available

The aim of this work is to target the production of age-specific production of hyperactive platelets as a therapeutic platform to control clot formation that causes thrombosis, stroke, heart attacks, and other cardiovascular disease, as well as platelet overproduction disorders such as essential thrombocytosis. In particular, this effort specifically targets cells that have progressed down an age-specific differentiation pathway. These age specific platelets are hyperactive relative to platelets from younger progenitor cells. These older platelet progenitor cells have been characterized molecularly and functionally characterization and can be targeted using pharmacological, antibody-based, cell based or gene therapy based strategies to control clot formation and platelet activity and numbers.

Researchers at the University of California, Davis have developed ibogaine-related compounds that promote neural plasticity and treat neuropsychiatric and neurological disorders.

Researchers at the University of California, Davis have developed non-hallucinogenic compounds with clinically relevant therapeutic efficacy that promote neural growth and plasticity.

Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.

MCFAs provide a synergistic bactericidal effect in combination with antibiotics and bacteriophages to effectively treat antibiotic-resistant bacterial infections.

Brief description not available

Brief description not available

Researchers at the University of California, Davis have developed a therapy that combines bioactive lipids with antiretroviral drugs to accelerate viral suppression and promote gut mucosal repair in HIV treatment.